Skip to content
TrialScanner

NCT04780516

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

No phase registeredActive, not recruitingABBVLead

Registry record

Lead sponsor
AbbVie
Conditions
Psoriasis
Primary completion
Jan 2, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04780516 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04780516: Study to Assess Change in... | TrialScanner